BCR-ABL1 compounds

BCR-ABL1 compounds are a series of small molecule inhibitors developed by Far Biotech that target the BCR-ABL1 fusion protein, a constitutively active tyrosine kinase and the primary driver of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Utilizing its proprietary Quantum AI platform, Far Biotech has identified both allosteric and active-site binding compounds designed to overcome resistance mutations, such as the T315I gatekeeper mutation, which often render traditional orthosteric inhibitors ineffective. The program has achieved preclinical validation, demonstrating the potential of these chemotypically diverse leads to arrest leukemic cell proliferation by inhibiting the oncogenic signaling pathways mediated by the BCR-ABL1 kinase.

Other names

BCR-ABL1 compoundsBCR-ABL-1 compoundsBCR-ABL 1 compoundsBCR-ABL1 inhibitorsBCR-ABL-1 inhibitorsBCR-ABL 1 inhibitorsBCR-ABL1 small molecule inhibitorsBCR-ABL-1 small molecule inhibitorsBCR-ABL 1 small molecule inhibitors